Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets
Open accessAbstract
AIMS: To investigate treatment patterns and achievement of glycemic targets in patients with type 2 diabetes mellitus treated with basal insulin in a real-world setting, and to determine physicians' beliefs and practices regarding these patients. METHODS: This study had two components; a retrospective analysis using a US claims database of patient and treatment data, and a survey of physicians' beliefs and practices. RESULTS: A total of 39,074 patients treated with basal insulin were included in this analysis. The proportion of patients achieving HbA1c<7.0% (53mmol/mol) was similar in ongoing basal insulin users at baseline (26%) and at 3months follow-up (27%). The number of new initiators achieving HbA1c<7.0% (53mmol/mol) increased from baseline (11%) to 3months (27%). In the physician survey component, the majority of physicians indicated they would continue to increase basal insulin dose as long as was needed to reach HbA1c/fasting blood glucose goals (85% of physicians treating 'not on-goal' patients, 78% of physicians treating 'on-goal' patients). Physician-perceived barriers to insulin intensification included patient's lifestyle, non-adherence, and concerns about out-of-pocket costs. CONCLUSIONS: A large proportion of patients on insulin-based therapy fail to reach glycemic goals. More education of clinicians may improve insulin intensification rates and increase the proportion of patients reaching glycemic targets.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A large proportion of patients with type 2 diabetes receiving basal insulin do not achieve target HbA1c <7.0%.
“Despite significant expansion on our insulin portfolio during the past decade, a large proportion of patients with type 2 diabetes receiving basal insulin do not achieve target HbA1c <7.0%.4,6,25”
From Efficacy of a Smart Insulin Pen Cap for the Management of Patients with Uncontrolled Type 2 Diabetes: A Randomized Cross-Over Trial (2023) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 24 · Cited by 60
- Authors
- Dalal, M. R., Grabner, M., Bonine, N., Stephenson, J. J., DiGenio, A., & Bieszk, N.
- Affiliations
- Takeda Oncology (United States) (US)
- Carelon Research (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Dalal, Mehul R.
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 121
- Pages
- 17-26
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W2517165909
- Cited by
- 60
- References
- 24
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 8 · 2019: 15 · 2018: 9 · 2017: 6
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Research and Clinical Practice (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Sanofi US, Inc
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, basal insulin, glycemic control, HbA1c targets, insulin intensification, physician beliefs, treatment patterns, medication adherence, out-of-pocket costs, patient lifestyle
- MeSH terms
- Achievement, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Health Expenditures, Female, Goals, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Health Knowledge, Attitudes, Practice, Male, Middle Aged, Surveys and Questionnaires, Retrospective Studies, Databases, Factual, Glycemic Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review